Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series

Relapsed/refractory acute myeloid leukemia (R/R AML) carries a poor prognosis. We report three patients with R/R AML, each of whom had relapsed after at least two prior chemotherapy regimens or hematopoietic stem-cell transplantation (HSCT), treated with chidamide, decitabine, venetoclax, and low-do...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Qing Li, Jie Ji, Yu Wu
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2026-02-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	case series chidamide combination therapy epigenetic therapy relapsed/refractory acute myeloid leukemia (R/R AML) single-center study
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1760614/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!